NIC-0102

• UNSPSC Description:

  NIC-0102 is an orally active proteasome inhibitor (pIC50=7.55) that specifically inhibits NLRP3 inflammatory vesicle activation. NIC-0102 shows potent anti-inflammatory effects in a model of dextran sulfate sodium (DSS)-induced ulcerative colitis. NIC-0102 also inhibits production of pro-IL-1β[1].

• Target Antigen:

  NOD-like Receptor (NLR); Proteasome

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation;Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/nic-0102.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC(C[C@@H](B(O)O)NC([C@@H](NC(C1=C(C=CC=C1F)F)=O)CC2=CC=CC=C2)=O)C

• Molecular Weight:

  418.24

• References & Citations:

  [1]Wu X, et al. Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity. J Med Chem. 2022 Sep 5.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2806031-94-5